COVID-19 trials registries data warehouse

 Return to trial list

Trial - IRCT20131221015878N4


Column Value
Trial registration number IRCT20131221015878N4
Full text link
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

First author
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Dr.Alireza Biglari

Contact
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

biglari63@hotmail.com

Registration date
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

2022-02-26

Recruitment status
Last imported at : Sept. 29, 2022, 12:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Completed

Study design
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

nonRCT

Allocation
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Non-randomized

Design
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Parallel

Masking
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Open label

Center
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

single-center

Study aim
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Prevention

Inclusion criteria
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Signed written informed consent Able to follow the vaccination schedules, visits and tests General health or having controlled underlying diseases (based on the physician's diagnosis) Iranian citizenship Residents of Tehran Both sexes (male and female) Aged 18-80 years Receiving the initial 2 doses of Sinopharm within a 28±5 days interval Completion of the 2-dose Sinopharm vaccination course within 3-6 months prior enrollment.

Exclusion criteria
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Having a history of vaccination against Covid-19 with other vaccines (in addition to 2 doses of Sinopharm) History of COVID-19 based on laboratory or clinical evidence after receiving 2 doses of Sinopharm History of any vaccinations except COVID-19 within 3 months prior to enrollment Pregnant or breastfeeding women or those who intend to become pregnant up to 3 months after the booster dose injection Lifetime history of severe allergic reactions (anaphylaxis) to the vaccine Coagulation disorders that contraindicate with intramuscular injection History of treatment with immunosuppressive drugs 1 month before the booster injection (including oral and inhaled steroids (does not include topical steroids), cytostatic, interferon, immunoferon, transfer factor, Biomodulin T, any type of gammaglobin, levamisole , Heberferon, thymosin or any other immunomodulatory drug (including patients taking the above drugs due to an underlying disease) Having a fever or acute illness during the 7 days before the injection or on the day of the booster injection Suffering from an unstable heart disease

Number of arms
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

3

Funding
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Pasture Institute of Iran

Inclusion age min
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

18

Inclusion age max
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

80

Countries
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Iran

Type of patients
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Healthy volunteers

Severity scale
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

N/A

Total sample size
Last imported at : April 5, 2022, 8:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

225

primary outcome
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Increased Anti-Spike headline Increased Anti RBD headline Increased cVNT headline

Notes
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Phase
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Not reported

Arms
Last imported at : Feb. 26, 2022, 7:30 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

[{"arm_notes": "", "treatment_id": 2438, "treatment_name": "Pastocovac", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2439, "treatment_name": "Pastocovac-plus", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]